Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Beta2-microglobulin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Beta2-microglobulin. Displaying page 1 of 1.
    EudraCT Number: 2008-008045-38 Sponsor Protocol Number: SS-BEL-01 Start Date*: 2009-06-23
    Sponsor Name:AZIENDA OSPEDALIERA S. MARIA DELLA MISERICORDIA
    Full Title: A Phase 2, proof of concept, 52-Week Open Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with primary Sjög...
    Medical condition: Subjects with have a diagnosis of primary SS according to the updated American European Consensus Group Criteria (8). In addition, patients must be always positive for anti-SSA or anti-SSB antibod...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021428 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002071-42 Sponsor Protocol Number: HIV-IMMUNESARTAN Start Date*: 2012-01-16
    Sponsor Name:Fundació Clínic de Recerca Biomèdica
    Full Title: Effects of losartan and antiretroviral regimen containing raltegravir in fibrosis inflammation mediators, cardiovascular risk and neurocognitive disorders in HIV infected patients previously eff...
    Medical condition: HIV seropositive
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008919 Chronic HIV infection LLT
    14.1 10021881 - Infections and infestations 10058315 HIV disease progression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012337-29 Sponsor Protocol Number: IILFLE09 Start Date*: 2009-07-20
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma
    Medical condition: Elderly patients with advanced stage previously untreated follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003374-40 Sponsor Protocol Number: 1-2016 Start Date*: 2016-11-29
    Sponsor Name:University of Tartu
    Full Title: The effects of augmented renal clearance on the pharmacokinetic/pharmacodynamic profile of piperacillin/tazobactam in children and young adults with malignant or non-malignant haematological or onc...
    Medical condition: The state of renal hyperfiltration during infection in children and young adults with malignant or non-malignant haematological or oncological diagnosis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004241-32 Sponsor Protocol Number: EDOLAS Start Date*: 2020-02-07
    Sponsor Name:SOCIETA' ITALIANA MALATTIE INFETTIVE E TROPICALI
    Full Title: Efficacy and safety of early switching to dolutegravir/lamivudine (DTG/3TC) from INSTI-based three-drug regimens in HIV-1-infected adults previously naïve who achieve virological suppression
    Medical condition: HIV-1 infected individuals currently taking an INSTI-based three-drug first-line regimen for less than 18 months and who have been virologically suppressed with HIV-1 RNA <50 copies/mL
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10068341 HIV-1 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 00:21:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA